Merck Signs Up to $4.5B Oncology Deal with Seattle Genetics

Share this

Merck Signs Up to $4.5B Oncology Deal with Seattle Genetics


  • Seattle Genetics to receive $600M up front- $1B as equity investment- 5M shares of Seattle Genetics common stock at a price of $200/ share- ~$2.6B as milestones including $850M development milestones and $1.75B as commercial milestones. The companies will equally share costs and profits on the global development of ladiratuzumab vedotin and other LIV-1-targeting ADCs
  • The companies will co-commercialize the therapy in the US and EU. Seattle Genetics will be responsible for approval in the US & Canada and will record sales in the US- Canada- and EU while Merck will be responsible for approval in EU & outside the US & Canada- and will record sales in countries outside the US- EU- and Canada
  • Additionally- companies enter exclusive license and co-development agreement to accelerate the global reach of Tukysa for HER2+ cancers in regions outside the US- EU & Canada. As per the agreement- Seattle Genetics to receive $125M as upfront and is eligible to receive up to $65M as progress-dependent milestones- $85M as research and development milestones- and royalties on sales of Tukysa in Merck’s territory

­ Ref: PRNewswire | Image: Merck 

Click here to­ read the full press release 


This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions